Recognition and treatment of genitourinary complications in paediatric Crohn's disease using Infliximab.
Although genitourinary complications of Crohn's are well recognized, available information regarding their clinical course and management is sparse especially in the paediatric population. We report a myriad of urological complications in five paediatric cases, our experience from a tertiary paediatric urological and gastroenterological centre. All children with urological complications had severe Crohn's disease which necessitated the use of immuno-suppressants including Infliximab. Three of four children healed and closed their fistulas after treatment, although failed to avoid future surgery, albeit for other reasons.


CONCLUSIONS
We suggest Infliximab should be considered as a treatment option but in the absence of a common consensus, treatment be tailored to individual cases.
Afzal
N A
NA
Department of Paediatrics, Southampton University Hospital NHS Trust, Southampton, UK. N.Afzal@soton.ac.uk
Shenoy
M U
MU
Haque
S
S
Wilcox
Dt
D
Shah
N
N
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000150:complications*; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy* / Q000209:etiology; D006776:Hospitals, Pediatric; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008131:London; D008297:Male; D052801:Male Urogenital Diseases / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab